UNSPSC 51334312: Clopenthixol hydrochloride

This classification denotes the hydrochloride form of a dopamine antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0A432D932A. European Medicines Agency schedules Clopenthixol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06736MIG. Clopenthixol generally arises in the molecular formula C22H25CLN2OS.

UNSPSC 51334312 Clopenthixol hydrochloride is a Commodity code that nominally covers a single pharmaceutical active ingredient, but recent state and local activity shows little procurement directly aligned with this specific drug. The code shows sparse relevant solicitation activity; the recent opportunities tagged to this UNSPSC involve broader pharmaceutical procurement (generic multi-source drugs and over-the-counter products through cooperative purchasing, naloxone and drug deactivation systems through county health procurement, and therapeutic pharmacy program market research through a state health commission) rather than clopenthixol hydrochloride specifically. State and local buying under this code does not appear to be a distinct procurement stream.

The most visible activity involves cooperative purchasing vehicles and health agency procurement for pharmaceutical inventories serving multiple jurisdictions or community health initiatives. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP on January 20, 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon, requiring vendor compliance with cGMP, the Drug Supply Chain Security Act, and relationships with authorized wholesalers. Seminole County, Florida issued an IFB (due July 26, 2023) for naloxone and drug deactivation systems through a county community health program. The Texas Health and Human Services Commission issued an RFI in April 2026 to explore direct-to-manufacturer prescription programs. Geographic activity centers on Minnesota, Florida, and Texas. The code itself does not appear to drive meaningful state and local volume; firms pursuing pharmaceutical supply should track broader generic drug and OTC cooperative purchasing vehicles and health agency inventory solicitations rather than this specific ingredient code.